All relevant analyses are within the manuscript and its Supporting Information files. Primary data (whole slide images) will be made available upon request, as the WSIs are housed in WuPax which is also used as a platform for clinical use. Unrestricted access may cause server to function suboptimally and jeopardize clinical work flow. We do intend to grant access to all request for data, but prefer to be in a controlled fashion so as not to interfere with our clinical work flow. Interested parties can contact data access guarantor Jared Amann-Stewart at <amann-stewartj@wustl.edu>.

Introduction {#sec005}
============

Undernutrition remains ubiquitous in low- and middle-income countries (LMICs) and underlies over 40% of child deaths \[[@pntd.0007975.ref001]\]. Wasting, an indicator of acute malnutrition, and defined as weight-for-height standard deviation z score (WHZ) \<-2, afflicts 7.3% of children under age five \[[@pntd.0007975.ref002]\]. Severe acute malnutrition (SAM) is defined as WHZ \<-3, mid-upper arm circumference \<11.5 cm among 6-59-month olds, or the presence of nutritionally-induced bilateral pitting edema. This latter condition is also known as kwashiorkor \[[@pntd.0007975.ref003], [@pntd.0007975.ref004]\]. Poor linear growth is a reflection of chronic undernutrition. Stunting, defined as height-for-age z score (HAZ) \<-2, is used to indicate the prevalence of the problem at the population level. Stunting is associated with increased risk of mortality and developmental delay among children and non-communicable diseases and reduced human capacity into adulthood \[[@pntd.0007975.ref001]\]. An estimated 22% or 150 million children younger than 5 years of age are stunted \[[@pntd.0007975.ref002]\].

Even the most optimal food-based interventions have limited effects on preventing or correcting linear growth deficits \[[@pntd.0007975.ref005]--[@pntd.0007975.ref008]\]. Recently, attention has been directed towards environmental enteric dysfunction (EED) as an important component to suboptimal childhood growth, in particular, poor linear growth \[[@pntd.0007975.ref009]--[@pntd.0007975.ref013]\]. EED is an underdiagnosed, highly prevalent condition among children in LMICs \[[@pntd.0007975.ref014]--[@pntd.0007975.ref018]\]. EED has been variably termed tropical enteropathy or environmental enteropathy, and was first described as an acquired malabsorption syndrome among adult westerners residing in LMICs \[[@pntd.0007975.ref019]--[@pntd.0007975.ref021]\]. A common histologic feature is small intestinal villous blunting, but its etiology remains elusive \[[@pntd.0007975.ref022]\]. The working hypothesis is that an environmental driver, including recurrent or persistent enteric infection, infections from specific pathogen(s), an abundance of nonpathogenic fecal microbes, or distortion of intestinal microbiota composition, could precipitate and/or perpetuate the small bowel response. This process is analogous to the small bowel response to gluten in gluten-sensitive enteropathy (GSE), also known as celiac disease \[[@pntd.0007975.ref009], [@pntd.0007975.ref011], [@pntd.0007975.ref023]\].

After a flurry of biopsy studies four decades ago \[[@pntd.0007975.ref024]--[@pntd.0007975.ref028]\], there has been a paucity of histologic studies of the small bowel until recently. However, markers in blood, stool, and urine (e.g., urine dual sugar permeability testing) have lent credence to the concept that poor growth and EED are tightly linked in children in LMICs \[[@pntd.0007975.ref014], [@pntd.0007975.ref029]--[@pntd.0007975.ref032]\]. Nonetheless, the origin and pathophysiology of EED remains elusive. This knowledge gap is in part attributable to the limited understanding of the histologic changes associated with this disorder and how they compare to other enteropathies including GSE, which shares features of an environmental trigger and villous blunting on histology \[[@pntd.0007975.ref033]\]. While GSE has not been identified as a prevalent disorder in sub-Saharan Africa and South Asia (outside of India), enteropathy has been identified among children with SAM, especially kwashiorkor, in these settings \[[@pntd.0007975.ref034]--[@pntd.0007975.ref038]\].

Based on existing data from cohort studies in diverse populations \[[@pntd.0007975.ref014]--[@pntd.0007975.ref018]\], we hypothesized that a histology index using an unbiased approach will allow identification of histopathologic features unique to EED as well as those shared with other enteropathies, and/or identify histologically-identifiable subsets of EED. Here we present the first EED histology index, agnostically constructed and encompassing tissue injury and response patterns commonly observed in clinical practice, in an attempt to improve our understanding of the histopathology underlying this entity or entities. We also describe the rigorous testing used to assess its reproducibility, by applying the scoring index to two distinct cohorts with suboptimal growth recruited from distinct geographic locations where EED is prevalent and North American GSE and control cohorts.

Methods {#sec006}
=======

Study cohorts {#sec007}
-------------

Endoscopic duodenal biopsies from four cohorts were analyzed: (1) Hospitalized 6--36 month olds with SAM and persistent diarrhea in Lusaka, Zambia \[[@pntd.0007975.ref039]\]; (2) children 18--22 months with non-edematous wasting not requiring hospitalization recruited from a community-based birth cohort in rural Pakistan, and undergoing endoscopy if unresponsive to 2 months of outpatient nutritional intervention \[[@pntd.0007975.ref040]\]; (3) children \<18 years with clinically suspected GSE; and (4) children \<18 years with normal tissue transglutaminase (tTG) IgA concentrations, no known inflammatory bowel disorders or prior GSE diagnosis, and in whom a diagnostic upper endoscopy was indicated (**[Table 1](#pntd.0007975.t001){ref-type="table"}**). The latter two groups underwent endoscopy as part of routine clinical care at the Washington University School of Medicine/St. Louis Children\'s Hospital (St. Louis, Missouri). Exclusion criteria for Zambian and Pakistani cohorts consisted of neurologic, cardiac, congenital, or other conditions associated with failure to thrive; diagnosis with GSE based on elevated tTG IgA concentrations as also an exclusion criteria for the purposes of this EED histopathology scoring index initiative. Children were excluded from the GSE cohort if they had known inflammatory intestinal disorders or a prior history of GSE.

10.1371/journal.pntd.0007975.t001

###### Cohort inclusion and exclusion criteria.

![](pntd.0007975.t001){#pntd.0007975.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                    Pakistan                                                                                                                                                                                                           Zambia                                                                                                                                                            St. Louis GSE                                                                                                                                                                        St. Louis controls
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------
  **Age criteria for enrollment**   \< 18 months                                                                                                                                                                                                       6--36 months                                                                                                                                                      \< 18 years                                                                                                                                                                          \< 18 years

  **Age at endoscopy**              18--22 months                                                                                                                                                                                                      6--36 months                                                                                                                                                      \< 18 years                                                                                                                                                                          \< 18 years

  **Inclusion criteria**            Non-edematous wasting not requiring hospitalization recruited from a community-based birth cohort in rural Pakistan, and undergoing endoscopy if unresponsive to 2 months of outpatient nutritional intervention   Hospitalized with SAM and persistent diarrhea                                                                                                                     Clinically suspected GSE based on elevated serum concentrations of IgA antibodies to tissue transglutaminase (tTG IgA) and with clinical histopathology results interpreted as GSE   Normal tTG IgA circulating concentrations in whom a decision was made to undergo upper endoscopy

  **Exclusion criteria**            Neurologic, cardiac, congenital, or other conditions associated with failure to thrive; excluded from present analysis if clinical diagnosis of GSE based on elevated tTG IgA concentrations                       Neurologic, cardiac, congenital, or other conditions associated with failure to thrive, or a clinical diagnosis of GSE based on elevated tTG IgA concentrations   Known inflammatory disorders of the gut or a known prior history of GSE\                                                                                                             Known inflammatory bowel disorders or prior diagnosis of celiac disease
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Anthropometric, clinical and laboratory assessments {#sec008}
---------------------------------------------------

The following information were collected across all four cohorts: age, sex, recumbent length (children \<two years of age), standing height ([\>]{.ul} two years of age), weight, and history of diarrhea. For convenience, henceforth we refer to both length and height as height. Clinical laboratory testing across all cohorts included hemoglobin, mean corpuscular volume (MCV), C-reactive protein (CRP), and tTG IgA concentrations were determined. tTG IgA assay normal limits differ depending assay kit; we expressed anti-tTG concentrations as percentages of upper limits of normal for the particular kit utilized (IBL International, Germany in Pakistan, Orgentech, Germany in Zambia, Inova, California, and Quest and Labcorp in St. Louis). Additionally, biomarkers potentially reflective of EED or undernutrition processes common to at least two sites' cohorts were analyzed in this report and included urinary dual sugar (lactulose, rhamnose or lactulose, mannitol) permeability testing (Zambia and St. Louis)\[[@pntd.0007975.ref041]\], and serum concentrations of insulin-like growth factor 1 (IGF-1) and glucagon-like peptide 2 (GLP-2) (Zambia and Pakistan). Individual data are included in **[S1 Dataset](#pntd.0007975.s007){ref-type="supplementary-material"}**.

Duodenal endoscopic biopsy {#sec009}
--------------------------

In the Pakistan cohort, two to three biopsies from the second portion of the duodenum were taken and each biopsy was embedded in an individual paraffin block. In Zambia, typically three biopsies were collected from the second part of the duodenum for each patient. In the St. Louis site, children with suspected GSE had four biopsies taken from the second portion of the duodenum and two from the bulb, while control children had 2 biopsies from the second portion of the duodenum, per that site's clinical protocol \[[@pntd.0007975.ref042]\]. No adverse events were noted during or after the procedure. In Zambia and St. Louis, all biopsies from the same child were embedded in a single paraffin block. In Zambia, all biopsies were collected and oriented under a microscope within 10 minutes before fixation. No additional orientation step was taken before fixation for Pakistani, GSE, and control biopsies.

Digital pathology workflow {#sec010}
--------------------------

Whole slide images (WSI) were scanned at 20x magnification from hematoxylin & eosin (H&E) stained slides. The slides from the Pakistan cohort were scanned at Aga Khan University using an Olympus VS120 (Tokyo, Japan) scanner. The slides from the Zambian and St. Louis sites were scanned using an Aperio Scanscope CS scanner at the Washington University Department of Pathology. All WSIs were uploaded to the Washington University Digital Pathology Exchange (WUPax) picture archiving and communication system, a secure browser-based platform developed in 2015 by the Washington University Department of Pathology to meet clinical needs of geographically separated institutions. WUPax is in routine clinical use in a College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Act (CLIA)-licensed, and Health Insurance Portability and Accountability Act of 1996 (HIPAA)-compliant environment \[[@pntd.0007975.ref043], [@pntd.0007975.ref044]\], and has also been adapted for research purposes.

EED scoring index histology criteria {#sec011}
------------------------------------

The EED scoring index was developed by three gastrointestinal pathologists (T.C.L., O.Y., C.A.M.), with input from EED experts who are members of the EED Biopsy Initiative Consortium. This system was developed using a hypothesis-free approach by which common and potential features of small intestinal injury patterns were all included, and scored using semi-quantitative categorical measures)\[[@pntd.0007975.ref045]\]. The three pathologists accessed the WSIs within WUPax. The features included in the scoring index, the definitions of these features, and the scoring options were refined through a series of four iterative reads of subsets of WSIs from the four cohorts. The process also included identifying parameters that merited efforts for improved inter-observer concordance (see Statistical analysis section below). Following these processes, the complete set of WSIs was scored by the three pathologists using the final histology index, and inter-observer concordance was determined. During each set of reads, the pathologists recorded their scores independently and were blinded to cohort identity and each other's scores. A histology atlas was developed (C.A.M.) as a guide for applying the scoring index can be accessed at **[S1 Atlas](#pntd.0007975.s006){ref-type="supplementary-material"}**.

The pathologists scored each WSI as a subjective average across tissue fragments within that WSI. Because the biopsies for the same individual in Zambia and St. Louis were embedded in a single paraffin block, they were therefore processed into a single H&E slide and WSI. However, in Pakistan each biopsy was placed into a single paraffin block, multiple slides and WSIs were available for individual children, enabling us to assess intra-individual score variability between biopsies for this cohort.

Statistical analysis {#sec012}
--------------------

Inter-observer agreement was assessed using multiple weighted estimates: percent agreement, kappa, and Gwet's agreement coefficient (AC). Spearman rank correlation was additionally used to assess correlation between pathologists on total histology score, a summed measure of histologic parameters. Statistical differences in histologic parameter scores between cohorts were assessed using the non-parametric Kruskal-Wallis test, appropriate for ordinal dependent variables, followed by Dunn\'s multiple comparisons test with Benjamini-Hochberg adjustment within tests, with the false discovery rate (FDR) set at 0.05; we did not adjust for FDR across analyses of different histologic score parameters.

Total histologic score percent was utilized in analyses instead of total histologic score to facilitate comparison across images. While the summed total histologic score would be affected by parameters marked as \'not scorable\', converting the score into a percent of total possible points (excluding points for non-scorable parameters) eliminates that issue.

Heterogeneity of total histology scores within and between children in the Pakistani cohort, where each WSI represented single biopsies, was analyzed using a cross-sectional mixed effects model with biopsies nested within each child. The intra-correlation coefficient was used to estimate and compare variances. Averages of scores for individual children were calculated across WSIs for comparative analyses with the other cohorts and relationships with patient characteristics so as not to over-represent one cohort.

Sample sizes were insufficient to conduct hypothesis-driven assessments between histopathology and patient characteristics; however, we did assess for associations as an exploratory analysis. Completeness of anthropometry, but not laboratory, data allowed for cohort-specific assessments of relationship to histology. HAZ, WHZ, body mass index z scores (BMIZ), and weight-for-age z scores (WAZ) were calculated based on World Health Organization (WHO) reference standards \[[@pntd.0007975.ref046]\], using WHO Anthro (version 3.2.2) \[[@pntd.0007975.ref047]\] and WHO Anthro Plus software (version 1.0.4) \[[@pntd.0007975.ref048]\]. Per WHO standards, WAZ was calculated only for children under 10 years of age, and BMI and BMIZ were calculated only for children over age 5 \[[@pntd.0007975.ref047]\]. Relationships between histologic scores and cross-sectional patient characteristics---anthropometrics, clinical parameters (history of diarrhea, HIV infection status), and laboratory markers---were assessed by linear regression with histologic scores treated as continuous predictors after assessment by Akaike information criterion (AIC) and Bayesian information criterion (BIC) in comparison with models using the categorical predictors. Models were adjusted for cohort. We did not adjust for multiple comparisons across regressions because of the exploratory nature of this analysis. Where variation in scores for a histologic parameter was minimal (i.e. representing [\<]{.ul}2 ordinal levels, with ordinal scoring parameters having either 4 or 5 response levels), we did not assess for a relationship. P-values were two-tailed, and alpha was defined as 0.05.

Statistical analyses were performed using Stata v. 15.0 (StataCorp, College Station, TX) and GraphPad Prism 7.0 (GraphPad Software, San Diego, CA).

Ethical considerations {#sec013}
----------------------

Institutional approval was granted by the Aga Khan University Ethical Review Committee (2446-Ped-ERC-13), University of Zambia Biomedical Research Ethics Committee (006-01-13)), and Washington University School of Medicine Human Research Protection Office (201505051). Written consent was obtained from parents for all participants.

Results {#sec014}
=======

Demographics and clinical parameters {#sec015}
------------------------------------

The demographics of the four cohorts are described in **[Table 2](#pntd.0007975.t002){ref-type="table"}**. The 16 children in the Zambian cohort, by study inclusion criteria, were younger (median age 16.5 months) than the Pakistani cohort (median age 22 months). The Zambian children were also, by inclusion criteria, more severely malnourished (e.g., 44% of the Zambian cohort had a WAZ \<-4 compared to 10% of the Pakistani cohort) and all had a recent history of diarrhea. Anemia (median hemoglobin 8.4 grams/deciliter \[g/dl\] and 9.6 g/dl, respectively) and microcytosis (median MCV 70.1 femtoliter \[fL\] and 62.0 fL, respectively) were common in both cohorts. The Pakistani children and St. Louis controls had CRP circulating concentrations within normal ranges while 31% of Zambian and 22% of the St. Louis GSE cohort had elevated CRP circulating concentrations. Median tTG IgA concentrations as a percent of the upper limit of normal were 5.8% and 5.2% in the Zambian and Pakistani cohorts, respectively.

10.1371/journal.pntd.0007975.t002

###### Demographics of the study cohorts.
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                                                                       Pakistan EED   Zambia EED      St. Louis GSE                                St. Louis Control
  -------------------------------------------------------------------- -------------- --------------- -------------------------------------------- -------------------------------------------
  Median age                                                           22 mos         16.5 mos        9.5 yrs                                      11.7 yrs
  IQR                                                                  20--23         21-Oct          5.2--11.7                                    10.2--14.5
  (range)                                                              (18--25)       (6--23)         (3.0--15.5)                                  (2.9--16.9)
  Sex (% female)                                                       54.5           37.5            76.9                                         100
  Prevalence of diarrhea N (%)                                         5 (50%)        16 (100%)       0                                            2 (33.3%)
  Diarrhea duration (among those with diarrhea)                                                                                                    
  \<14 days                                                            5              0               \-                                           0
    14--28 days                                                        0              11                                                           1
  [\>]{.ul}28 days                                                     0              5                                                            1
  WHZ score[\*\*](#t002fn003){ref-type="table-fn"}                                                    (\<5 yrs age)                                (\<5 yrs age)
  [\>]{.ul} 0                                                          0              0               2                                            1
  \<0 to [\>]{.ul}-1                                                   1              2               0                                            0
  \<-1 to [\>]{.ul}-2                                                  4              1               0                                            0
  \<-2 to [\>]{.ul}-3                                                  3              5               0                                            0
  \<-3 to [\>]{.ul}-4                                                  2              2               0                                            0
  \< -4                                                                0              6               0                                            0
  HAZ score                                                                                                                                         
  [\>]{.ul} 0                                                          0              1               9                                            1
  \<0 to [\>]{.ul}-1                                                   0              0               2                                            4
  \<-1 to [\>]{.ul}-2                                                  2              2               1                                            1
  \<-2 to [\>]{.ul}-3                                                  3              4               0                                            0
  \<-3 to [\>]{.ul}-4                                                  4              5               1                                            0
  \< -4                                                                1              4               0                                            0
  WAZ score[\*\*](#t002fn003){ref-type="table-fn"}                                                    (\<10 yrs age)                               (\<10 yrs age)
  [\>]{.ul} 0                                                          0              1               4                                            1
  \<0 to [\>]{.ul}-1                                                   1              1               0                                            0
  \<-1 to [\>]{.ul}-2                                                  0              0               2                                            0
  \<-2 to [\>]{.ul}-3                                                  5              0               1                                            0
  \<-3 to [\>]{.ul}-4                                                  3              7               0                                            0
  \< -4                                                                1              7               0                                            0
  BMIZ score[\*\*](#t002fn003){ref-type="table-fn"}                    n/a            n/a                                                           
  [\>]{.ul} 0                                                                                         11                                           4
  \<0 to [\>]{.ul}-1                                                                                  1                                            0
  \<-1 to [\>]{.ul}-2                                                                                 0                                            1
  \<-2                                                                                                1                                            1
  Median tTG Ab concentration as percentage of upper limit of normal   5.2            5.8             681.3[\*](#t002fn002){ref-type="table-fn"}   18.0[\*](#t002fn002){ref-type="table-fn"}
  IQR                                                                  4.2--6.4       5.2--6.8        510.1--1833.3                                12.5--27.3
  (Range)                                                              (2.4--7.2)     (4.8--19.9)     (176.1--4443.3)                              (11.0--66.3)
  Median hemoglobin concentration (g/dl)                               9.6            8.4             12.7                                         13.5
  IQR                                                                  8.1--11.0      7.7--8.9        11.6--13.2                                   12.9--14.1
  (Range)                                                              (7.1--12.4)    (6.1--9.8)      (10.1--14.2)                                 (12.7--14.1)
  Missing                                                              0              2               3                                            2
  Median mean corpuscular volume (fL)                                  62             70.1            80.2                                         83.9
  IQR                                                                  56.3--74.4     65.6--77.3      79.2--83.1                                   78.0--89.7
  (Range)                                                              (49.3--82.4)   (61.1--87.0)    (78.8--92.0)                                 (77.3--90.2)
  Missing                                                              0              3               3                                            2
  Median C-reactive protein (CRP; ng/ml)                               102            1230.8          432.6                                        307.9
  IQR                                                                  37--199        530.4--4261.3   163.3--610.2                                 268.7--549.7
  (Range)                                                              (14--212)      (47.5--21000)   (40.4--9322.4)                               (179.1--1888.1)
  Missing                                                              4              0               4                                            0

Abbreviations: Ab, antibody; BMIZ, body mass index z score; CRP: C-reactive protein; EED, environmental enteric dysfunction; fL, femtoliter, GSE, gluten sensitivity enteropathy; HAZ, height-for-age z score; IQR, interquartile range; mos, months; n/a, not applicable; SAM, severe acute malnutrition; tTG Ab, tissue transglutaminase antibody; tTG IgA, tissue transglutaminase immunoglobulin A; WAZ, weight-for-age z score; WHZ, weight-for-height z score; yrs, years.

\* Data imputed for two children with GSE and one control based on readings that were imprecise/ out-of-measurement range (\>100 and \<2, respectively). For children with GSE, we imputed the median of all precise measurements over 100 (n = 5, median 133.3; range 102.0--146.7). For the control child, we imputed the maximum possible value (1.99).

\*\* WHO growth reference standards for WAZ and WHZ scores extend to less than 120 months and BMIZ scores start at 120 months.

The St. Louis cohorts (13 GSE and 6 control participants) were older: median age 9.5 and 11.7 years, respectively. One child in each of the St. Louis cohorts had a BMIZ score \<-2, and one child in the GSE cohort had both weight-for-age z score (WAZ) and HAZ \<-2. All controls had WAZ and HAZ \>-2. No GSE participants had a recent history of diarrhea, compared to 33% of controls. The median tTG IgA concentration was 6.8x and 18% of the normal limit for the GSE and control cohorts, respectively. Hemoglobin concentrations were normal among the controls while one child with GSE (representing 10% of GSE children with hemoglobin data) had a hemoglobin \<11 g/dl. MCV ranges in both cohorts were normal.

Anthropometric, clinical, and laboratory parameters between the two LMIC study cohorts did not statistically significantly vary except that, per inclusion criteria, the Zambian cohort were younger, had diarrhea of longer duration, and lower WHZ score (**[S1A--S1C Fig](#pntd.0007975.s009){ref-type="supplementary-material"}**). There was no significant difference in hemoglobin across the cohorts (**[S1D Fig](#pntd.0007975.s009){ref-type="supplementary-material"})** and tTG IgA also did not differ between these groups (**[S1E Fig](#pntd.0007975.s009){ref-type="supplementary-material"}**).

High inter-observer reproducibility using EED histology scoring index {#sec016}
---------------------------------------------------------------------

The histology scoring index assigns a 4--5 tier categorical value to each of the 11 histopathological parameters representing various injury response mechanisms (**[Table 3](#pntd.0007975.t003){ref-type="table"}**). Features with 4-tier grading include: acute (neutrophilic) inflammation, chronic inflammation, eosinophil infiltration, intramucosal Brunner glands, foveolar cell (gastric mucin cell) metaplasia, Paneth cell density, and enterocyte injury. Features with 5-tier grading include: intraepithelial lymphocytes (IELs), villous architecture, goblet cell density, and epithelial detachment. In addition, a total histologic score is calculated as a sum of the individual parameters, and ranges from 0 to 37. Because individual parameters could potentially be deemed "not determinable" because of slide preparation or other quality issues, we also calculated another summative score as a percentage (total histologic score percent), to account for instances where the denominator was \<37.

10.1371/journal.pntd.0007975.t003

###### Histologic category and scoring scheme.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  **Acute (neutrophilic) inflammation**                                                                                                                                                                                      **0**: PMNs may be present in vessels or in lamina propria, but there is no intraepithelial infiltration (cryptitis,\
                                                                                                                                                                                                                             villitis)

  **1**: 1--2 foci of epithelial neutrophilic infiltration or crypt microabscesses                                                                                                                                           

  **2**: \> 2 foci of epithelial neutrophilic infiltration or crypt microabscesses, but ≤ 50% of mucosa involved                                                                                                             

  **3**: \> 50% of mucosa involved by epithelial neutrophilic infiltration                                                                                                                                                   

  **Eosinophil infiltration**\                                                                                                                                                                                               **0:** No increase in eosinophils (highly scattered in lamina propria, no intravillous or intercryptal space with \> 5 eosinophils)

  **1:** Increased eosinophils (intravillous or intercryptal space with \> 5 eosinophils) involving ≤ 50% of mucosa, with no eosinophilic crypt microabcesses                                                                

  **2:** Increased eosinophils (intravillous or intercryptal space with \> 5 eosinophils) involving \> 50% of mucosa, or up to 1 focus of eosinophilic epithelial infiltration or crypt microabcesses per mucosal fragment   

  **3:** \> 2 foci of eosinophilic epithelial infiltration or crypt microabcesses in any mucosal fragment                                                                                                                    

  **Chronic inflammation**\                                                                                                                                                                                                  **0:** No qualitative increase in mononuclear inflammatory cells (MIC) in lamina propria. Majority of villous bases contain \< 3 MIC across, on average.

  **1:** Increased MIC, based on villous base displaying 3--5 MIC across, on average.                                                                                                                                        

  **2:** Increased MIC, based on villous base displaying 6--10 MIC across, on average.                                                                                                                                       

  **3:** Increased MIC, based on villous base displaying \> 10 lymphocytes on average.                                                                                                                                       

  **Intraepithelial lymphocytes**\                                                                                                                                                                                           **0:** IEL ratio of lymphocytes to enterocytes \< = 20% in any area

  **1:** Lymphocyte/epithelial ratio \> 20%, but ≤ 50%, in \< = 50% of mucosa                                                                                                                                                

  **2:** Lymphocyte/epithelial ratio \> 20%, but ≤ 50%, in \> 50% of mucosa                                                                                                                                                  

  **3:** Lymphocyte/epithelial ratio \> 50% in ≤ 50% of mucosa                                                                                                                                                               

  **4:** Lymphocyte/epithelial ratio \> 50% in \> 50% of mucosa                                                                                                                                                              

  **Villous architecture**\                                                                                                                                                                                                  **0:** Majority of villi are \> 3 crypt lengths long

  **1:** Villi are ≤ 3 but \> 1 crypt length long, with abnormality in ≤ 50% of mucosa.                                                                                                                                      

  **2:** Villi are ≤ 3 but \> 1 crypt length long, with abnormality in \> 50% of mucosa                                                                                                                                      

  **3:** Villi absent, or ≤ 1 crypt length long, with abnormality in ≤ 50% of mucosa                                                                                                                                         

  **4:** Villi absent, or ≤ 1 crypt length long, with abnormality in \> 50% of mucosa                                                                                                                                        

  **Intramucosal Brunner glands**\                                                                                                                                                                                           **0:** Brunner glands are in submucosa, but are not observed above the muscularis mucosae

  **1:** 1--2 foci, none involving \> 5 crypt bases                                                                                                                                                                          

  **2:** 3--5 foci, none involving \> 5 crypt bases                                                                                                                                                                          

  **3:** \> 5 foci, or any area of intramucosal Brunner glands involving \> 5 crypt bases                                                                                                                                    

  **Foveolar cell metaplasia**\                                                                                                                                                                                              **0:** Only absorptive enterocytes and goblet cells observed on villi, no evidence of foveolar cells

  **1**: Foveolar mucin cells observed, usually on the tips of the villi; 1--2 villous tips involved                                                                                                                         

  **2:** Foveolar mucin cells observed, usually on the tips of the villi; 3--5 villous tips involved                                                                                                                         

  **3:** Foveolar mucin cells observed, usually on the tips of the villi; \> 5 villous tips involved                                                                                                                         

  **Goblet cell density**\                                                                                                                                                                                                   **0:** Normal goblet cell density (at least 1 goblet cell per 20 enterocytes) in all evaluable mucosal epithelial layer

  **1:** Decreased goblet cells (\< 1/20 enterocytes) in 1--25% of evaluable mucosal epithelium                                                                                                                              

  **2:** Decreased goblet cells (\< 1/20 enterocytes) in 26--50% of evaluable mucosal epithelium                                                                                                                             

  **3:** Decreased goblet cells (\< 1/20 enterocytes) in 51--75% of evaluable mucosal epithelium                                                                                                                             

  **4:** Decreased goblet cells (\< 1/20 enterocytes) in 76--100% of evaluable mucosal epithelium                                                                                                                            

  **Paneth cell density**\                                                                                                                                                                                                   **0:** ≥ 5 Paneth cells/ crypt, on average

  **1:** 2--4 Paneth cells/ crypt, on average                                                                                                                                                                                

  **2:** \< 2 Paneth cell/crypt, involving ≤ 50% of crypt bases                                                                                                                                                              

  **3:** \< 2 Paneth cell/crypt, involving \> 50% of crypt bases                                                                                                                                                             

  **Enterocyte injury**\                                                                                                                                                                                                     **0:** Majority of enterocytes (90%) show tall columnar morphology

  **1:** Enterocytes show low columnar (\< 2:1 L:W ratio), cuboidal or flat morphology, in ≤ 50% of mucosa                                                                                                                   

  **2:** Enterocytes show low columnar (≤2:1 L:W ratio), cuboidal or flat morphology, in \> 50% of mucosa                                                                                                                    

  **3:** Any area of mucosal erosion/ulceration                                                                                                                                                                              

  **Epithelial detachment**\                                                                                                                                                                                                 **0**: Complete coverage of mucosal surface by epithelial cells

  **1**: Surface epithelium missing or detached from \< 25% of mucosa                                                                                                                                                        

  **2**: Surface epithelium missing or detached from 25--50% of mucosa                                                                                                                                                       

  **3**: Surface epithelium missing or detached from 51--75% of mucosa                                                                                                                                                       

  **4**: Surface epithelium missing or detached from \> 75% of mucosa                                                                                                                                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------

Note: For chronic inflammation there is a response option "not scorable due to \<3 villi assessable or other slide quality issue", while for all other parameters there is a response option "not scorable due to slide quality or other factors".

There was good agreement across the three pathologists using the final histology index to score the WSIs (**[Table 4](#pntd.0007975.t004){ref-type="table"}**). Chronic inflammation, IELs and villous architecture shared the lowest percent agreement between pathologists (**[S2A and S2B Fig](#pntd.0007975.s010){ref-type="supplementary-material"}**). Concordance of total histology percent score was 84.0% weighted agreement, kappa 0.41, and Gwet\'s AC 0.55, and Spearman\'s correlations for pathologist pairs ranged from 0.58 to 0.74 (**[S1 Table](#pntd.0007975.s002){ref-type="supplementary-material"}**). The overall concordance across all parameters was 96% weighted agreement, kappa 0.70, and Gwet's AC 0.93. This level of concordance is comparable to those reported in other pathology studies \[[@pntd.0007975.ref049]--[@pntd.0007975.ref052]\].

10.1371/journal.pntd.0007975.t004

###### Concordance measures of EED duodenal histology index.

![](pntd.0007975.t004){#pntd.0007975.t004g}

  Histology feature                   \% agreement   Fleiss' Kappa   Gwet's AC
  ----------------------------------- -------------- --------------- -----------
  Acute (neutrophilic) inflammation   99.2           -0.01           0.99
  Eosinophil infiltration             96.2           0.12            0.96
  Chronic inflammation                68.9           -0.09           0.39
  Intraepithelial lymphocytes         76.4           0.32            0.45
  Villus architecture                 77.0           0.41            0.45
  Intramucosal Brunner glands         90.8           0.74            0.83
  Foveolar cell metaplasia            99.2           -0.01           0.99
  Goblet cell density                 84.5           0.21            0.72
  Paneth cell density                 81.4           0.48            0.60
  Enterocyte injury                   85.4           0.20            0.76
  Epithelial detachment               86.2           -0.02           0.78
  Total score percent                 84.0           0.41            0.55
  Overall concordance                 96.0           0.70            0.93

Cohort-specific histology features

Median total histology scores of the Zambian and Pakistani WSIs fell between those of the control and GSE cohorts (**[Fig 1](#pntd.0007975.g001){ref-type="fig"}**and **[Table 5](#pntd.0007975.t005){ref-type="table"}**; all p-values FDR-adjusted within tests). St. Louis control, Zambian, and Pakistani WSI total histology score percent distributions significantly differed from that of the GSE WSIs (p ≤0.0001, 0.02, and 0.0005, respectively). The distribution of Zambian WSI total score percent differed from those of the non-GSE controls (p = 0.01), while Pakistani WSI score percent did not (p = 0.20). Score percent distributions for Pakistani and Zambian WSIs did not differ significantly (p = 0.13).

![Total histology score percent, by cohort.\
Compared to the St. Louis GSE cohort, the St. Louis control, Pakistani and Zambian cohorts had lower total histology scores (p\<0.0001, p = 0.0005, and p = 0.02, respectively). Total histology score percent did not differ significantly between the Pakistani and Zambian WSIs (p = 0.13). Statistical analysis was performed by Kruskal-Wallis test followed by Dunn's multiple comparisons test with Benjamini-Hochberg correction for false discovery error rate. \*: p ≤ 0.05; \*\*: p ≤ 0.01; \*\*\*\*: p ≤ 0.0001. The bars indicate mean ± standard deviation.](pntd.0007975.g001){#pntd.0007975.g001}

10.1371/journal.pntd.0007975.t005

###### Median total histology score and total histology score percent by cohort.
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  Parameter (range of possible scores)                                        Pakistan     Zambia       St. Louis GSE   St. Louis Controls
  --------------------------------------------------------------------------- ------------ ------------ --------------- --------------------
  Median total score (0--37)                                                  9.3          11.5         15              2.3
  IQR                                                                         7.1--10.0    8.3--13.8    13.3--16.3      2.0--5.0
  Range                                                                       6.1--11.7    7.3--15.3    9.7--17.3       1.7--10.3
  Median total score percent (0--100)[^1^](#t005fn002){ref-type="table-fn"}   25.2         31.5         40.5            6.6
  IQR                                                                         19.2--27.5   23.0--37.9   36.0--45.0      5.4--14.1
  Range                                                                       16.5--31.8   21.1--43.8   29.1--48.0      4.7--29.7
  p value[^2^](#t005fn003){ref-type="table-fn"} compared to GSE               0.0005       0.02         \-              \<0.0001

Abbreviations: GSE, gluten sensitive enteropathy; IQR, interquartile range.

^1^ Compared to the GSE control group, Zambian WSI total score percent differed significantly (p = 0.01) while Pakistani WSI score percent did not (p = 0.20). Differences between Pakistani and Zambian cohorts were not significant (p = 0.13).

^2^ FDR-adjusted (within test) p-values.

**[Fig 2](#pntd.0007975.g002){ref-type="fig"}**(and **[S2 Table](#pntd.0007975.s003){ref-type="supplementary-material"}**) show the individual histology features for each cohort. Several patterns are discernible. Compared to the GSE WSIs, the Zambian and Pakistani WSIs had less chronic inflammatory infiltration of the lamina propria (**[Fig 2A](#pntd.0007975.g002){ref-type="fig"}**), and lower abundances of intramucosal Brunner glands (**[Fig 2B](#pntd.0007975.g002){ref-type="fig"}**). However, the Pakistani cohort had markedly increased IELs, with densities similar to those of the GSE cohort (**[Fig 2C](#pntd.0007975.g002){ref-type="fig"}**). In contrast, the Zambian cohort had notably fewer secretory lineage cells (goblet and Paneth cells; **[Fig 2D and 2E](#pntd.0007975.g002){ref-type="fig"}**), more enterocyte injury (**[Fig 2F](#pntd.0007975.g002){ref-type="fig"}**), a tendency toward epithelial detachment (**[Fig 2G](#pntd.0007975.g002){ref-type="fig"}**) and more severe villous architectural damage (**[Fig 2H](#pntd.0007975.g002){ref-type="fig"}**). There were no substantial neutrophilic inflammation, eosinophilic infiltration, or foveolar metaplasia in tissue from any cohort (**[S2 Fig](#pntd.0007975.s010){ref-type="supplementary-material"}**). Pathogens were only observed in the Pakistani cohort and limited to *Giardia* in five of 10 children's slide images (two of whom had *Giardia* detected in all of the WSI).

![Scores of individual histology features, by cohort.\
The GSE cohort had the highest scores in the categories of (A) chronic inflammation and (B) intramucosal Brunner's gland. Between the Pakistani and Zambian cohorts, the Pakistani cohort had (C) more intraepithelial lymphocytes. In contrast, the Zambian cohort had higher scores in the categories of (D) goblet cell density, (E) Paneth cell density, (F) enterocyte injury, and (G) epithelial detachment. The Zambian cohort also tended to have higher scores in (H) villous architecture derangement. Sample size: Pakistani n = 10, Zambian n = 16, GSE n = 13, control n = 6. \*: p ≤ 0.05; \*\*: p ≤ 0.01; \*\*\*: p ≤ 0.001; \*\*\*\*: p ≤ 0.0001. Statistical analysis was performed by Kruskal-Wallis test followed by Dunn's multiple comparisons test and corrected within tests for false discovery rate by the Benjamini-Hochberg method. The bars indicate mean ± standard deviation.](pntd.0007975.g002){#pntd.0007975.g002}

Heterogeneity of pathology findings in the Pakistani cohort {#sec017}
-----------------------------------------------------------

A distinguishing feature of the Pakistani study design is that each biopsy was allocated to single slides, thereby yielding multiple distinct WSIs per child for analysis of lesion patchiness. As seen in **[Fig 3A](#pntd.0007975.g003){ref-type="fig"}**, the maximal discrepancy between different biopsies from the same patient could generate a difference in total histologic percent score of \~5. Individual histologic features that tended to differ by ≥2 levels of pathology between biopsies from the same child include villous architecture (**[Fig 3B](#pntd.0007975.g003){ref-type="fig"}**) and the presence of intramucosal Brunner glands (**[Fig 3C](#pntd.0007975.g003){ref-type="fig"}**). In contrast, IEL, goblet cell and Paneth cell densities as well as chronic lamina propria inflammation were often only 1--2 levels apart between different biopsy specimens from an individual (**[S3 Fig](#pntd.0007975.s011){ref-type="supplementary-material"}**). Estimates of intra-class correlation from a multilevel model indicated that within-child variation exceeded between-child variation for total histologic score percent (57.4% vs. 42.6%, respectively, p = 0.013).

![Individual histology heterogeneity, Pakistani cohort.\
The scores for each individual biopsy for each subject were plotted for (A) total EED histology score percent, (B) villous architecture, and (C) intramucosal Brunner glands as these showed the highest variability between biopsies. The bars indicate mean ± standard deviation.](pntd.0007975.g003){#pntd.0007975.g003}

To determine if the reading of individual versus multiple biopsies may have affected the scoring reproducibility by the study pathologists, we took advantage of their assessment of the number of tissue fragments on each WSI. The cohort was divided into two sets, one in which the average number of tissue fragments was one (n = 15) and the other in which the average was \>1 (n = 46). The degree of agreement between the pathologists for the histologic parameters was approximately the same (**[Table 6](#pntd.0007975.t006){ref-type="table"}**and **[S2 Dataset](#pntd.0007975.s008){ref-type="supplementary-material"}**), indicating that the number of tissue fragments being assessed by the pathologists did not significantly contribute to the degree of histologic agreement.

10.1371/journal.pntd.0007975.t006

###### Overall concordance of histologic parameters based on number of tissue fragments assessed per image.

![](pntd.0007975.t006){#pntd.0007975.t006g}

  Single tissue fragment   Multiple tissue fragments                        
  ------------------------ --------------------------- ------ ------ ------ ------
  96.3                     0.69                        0.93   96.9   0.71   0.94
  95.5                     0.68                        0.91   96.5   0.70   0.93

Association of histology scores to patient characteristics {#sec018}
----------------------------------------------------------

We next determined if the histology scores correlated with clinical characteristics. HIV infection status in the Zambia cohort was not associated with total histology percent score or any individual histology parameter scores. After adjusting for site, total histologic score percent and the histology parameter scores were not significantly associated with HAZ, or WHZ in the combined study cohort. The only site-specific associations were identified in the Pakistani cohort, for which IEL density was inversely associated with all three anthropometric parameters: HAZ (ß = -1.1, 95% CI -1.8, -0.5; p = 0.004), WAZ (ß = -1.1, CI -2.1, -0.1; p = 0.03), and WHZ (ß = -0.8, CI -1.4, -0.2; p = 0.01). Also, in this cohort an unexpected positive association was observed between villous architecture score and LAZ (ß = 1.2, CI 0.4, 2.0; p = 0.008).

Adjusting for cohort, clinical laboratory and EED or growth biomarkers were similarly not significantly associated with histology total score percent or subscores, with one exception: IGF-1, measured in the EED cohorts only, was borderline associated with Paneth cell density (ß = -8.0, CI-15.7, -0.4; p = 0.04). No associations were found between histologic scores and lactulose: mannitol ratios (not performed in the Pakistani cohort, and half of the GSE and control subjects were tested for lactulose: rhamnose ratio), hemoglobin concentrations, MCV, CRP, tTG IgA (expressed as a percent of upper limit of normal) or GLP-2 concentrations. Several marginally significant relationships between histology scores and patient characteristics of small effect sizes were observed (**[S3 Table](#pntd.0007975.s004){ref-type="supplementary-material"}**).

Discussion {#sec019}
==========

Patterns of histologic changes in the gut have long been associated with both specific diarrheal and malabsorptive entities, as well as non-specific reactive/adaptive changes to injury. This includes histologic features that have been identified among individuals from indigenous populations and from travelers spending time in "tropical" areas that have experienced chronic malabsorption syndromes, so-called "tropical sprue" \[[@pntd.0007975.ref053]\]. Similar histologic changes have been noted in asymptomatic individuals in the same geographic areas, so-called" "tropical enteropathy", now referred to as environmental enteropathy or as EED \[[@pntd.0007975.ref010], [@pntd.0007975.ref054]\]. Among the issues that have hampered identification and subclassification of EED and the discovery of its underlying etiologies has been the lack of a robust and systematic method of categorizing and quantifying the intestinal histologic changes from cohorts of affected individuals.

To address this shortcoming in the field, we developed a histology index specific for duodenal biopsies that queries several distinct histologic parameters including quantity and type of various inflammatory cells and several epithelial differentiation lineage cells, mucosal architectural features, and epithelial cell injury patterns. Each parameter was given a numerical range of severity, with each numerical grade specifically defined. While the reproducibility between the three gastrointestinal pathologists in this study for grading the individual parameters varied, the overall score reproducibility was in the same range of interobserver reproducibility described for other accepted histology indices (overall kappa coefficient of 0.70), including those for grading inflammatory changes in ulcerative colitis (37) and due to *H*. *pylori* \[[@pntd.0007975.ref052]\]. Thus, the performance of the histology index described here appears to conform to the general performance of histologic assessment of tissue pathology and is suitable for use in comparing cohorts with enteropathies, including EED. IELs, chronic inflammation, and villous architecture were the parameters with the lowest inter-pathologist concordance. Inflammatory markers may be better assessed by special stains, such as immunohistochemistry. Villous architecture scores also had the widest range, compared to all other parameters. Quantitative morphometry may offer more precision in characterizing this feature, but such measurements are also labor intensive and require good tissue orientation on the slide. Future work should assess whether morphometry provides substantial gains in precision compared to subjective pathologist assessments "by eye".

Our data offer provisional guidance regarding the numbers of biopsies to be obtained when attempting to identify EED. Most notably, we found no significant difference in the overall concordance between pathologists for the histologic parameters based on the reading of a single tissue fragment (Pakistani), or multiple tissue fragments to generate a composite score from the tissue on the slide (Zambian). However, the Pakistani biopsies, apportioned into separate cassettes, demonstrate considerable within-host (i.e., inter-biopsy) variability. Specifically, the degree of discordance of overall histologic scores was greater between biopsies of the same child than between those of different children in the Pakistani cohort. The greatest intra-individual variability related to the assessment of intramucosal Brunner glands, which are known to have a focal and nodular appearance when increased in the duodenum \[[@pntd.0007975.ref040]\]. Because of its patchy nature, EED mucosal biopsy studies should include multiple biopsies, but pieces obtained can be considered as a pooled specimen set, to reduce the possibility of missing a case, to more comprehensively assess affected tissue, and to reduce analytic variability from sampling bias. This is standard endoscopic biopsy practice for diagnosing GSE \[[@pntd.0007975.ref055], [@pntd.0007975.ref056]\].

Our data demonstrate similarities and differences between the cohorts that warrant comment. While EED and GSE cohorts share histopathologic similarities, as suggested by prior studies \[[@pntd.0007975.ref026], [@pntd.0007975.ref040], [@pntd.0007975.ref057]--[@pntd.0007975.ref060]\], our index showed differences in the main histologic features that are classically associated with GSE, including intraepithelial lymphocytes. We also had the opportunity to compare a GSE case from Pakistan (excluded from this analysis) whose total histologic score was somewhat less severe than the median scores of the St. Louis GSE cohort, although overall showed a similar pattern of tissue injury (detailed comparison of scores to St. Louis GSE and Pakistani cohorts in **[S4 Table](#pntd.0007975.s005){ref-type="supplementary-material"}**). A single case does not permit generalizations about the overlap between EED and GSE pathology, but raises the possibility that GSE disease may be distinguishable from EED by histopathology, as has been suggested in previous literature as well \[[@pntd.0007975.ref026], [@pntd.0007975.ref040], [@pntd.0007975.ref057], [@pntd.0007975.ref059], [@pntd.0007975.ref060]\]. This may be most important in settings where both enteropathies co-exist.

There are several limitations of this current dataset. Due to ethical concerns, controls from EED endemic settings could not be included as endoscopic biopsies are invasive procedures that cannot be performed on otherwise healthy young children and clinical biopsies for non-enteropathy indications are quite rare at those sites. Along this line, while there were suggestions of cohort-specific histology features, we cannot exclude with certainty that the Zambian cohort findings are due to younger age, higher severity of the same enteropathy (namely EED), and/or contributions of a severe acute malnutrition-induced enteropathy. We attempted to perform an exploratory analysis of histopathology scores and patient characteristics but were hampered by samples sizes insufficient to detect significant associations. Such an analysis should be repeated with sufficiently powered data to test hypothesis driven approaches, and confirm or refute our findings, including those that were paradoxical (i.e., intramucosal Brunner gland density and villous architecture derangements with anthropometric Z scores) or not significant. EED might not be a globally applicable single entity. For example, there are differences between the intestinal lesions in the Pakistani and Zambian cohorts that we cannot readily explain, and might reflect genetics, environment, or the different indications for the endoscopic biopsies. Nonetheless, small bowel dysfunction appears to be a common finding in malnourished children in LMICs, and this report adds histologic data to recent attempts to better define EED for diagnostic and therapeutic purposes \[[@pntd.0007975.ref009], [@pntd.0007975.ref061]\]. Finally, it is also possible that as future data emerge regarding the causes and consequences of the histopathologic lesions we report and the concomitant clinical phenotypes, the entity we describe as EED might be superseded by new terminology. Nosologic reconsiderations might assign EED to be a specific enteropathy subtype, or EED itself might be subjected to its own variants.

It will be important to determine if the initial findings reported here extend to a larger and more diverse cohort of patients with EED. This scoring index is currently being applied to the approximately 550 biopsies by an expanded study team across five diverse sites: Zambia, Pakistan, Bangladesh and two North American comparison sites. This robust application will allow for refinement of the scoring system. This could include elimination of parameters that continue to demonstrate low performance in detection of EED and construction of a weighted algorithm of the index to more accurately define EED (e.g., certain parameters carry more weight toward the final score than others).

In summary, we described the development and validation of a new tool in the investigation of EED: a histology index designed for the study of small intestinal biopsies. The histology index can be used reproducibly by histopathologists to create parameter specific as well as overall pathology scores to compare to clinical and laboratory attributes in EED cohorts. The adoption of this index will aid not only in comparison of data within studies but in the comparison of data from separate studies. Given the durability of histologic specimens, there is an opportunity for this index to be used on archival samples from previous studies to provide historical comparison of cohorts in addition to those of contemporaneous and prospective studies. Perhaps most importantly, because the EED histopathology scoring index includes specific parameters indicative of injury processes, the system can be applied to identify histopathologic processes that distinguish EED from other enteropathies and to inform novel intervention targets and assess response to interventions.
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###### Clinical parameters, Zambian and Pakistani cohorts.

Due to differences in study design, the subjects in the Zambian cohort were (A) younger (p = 0.0012), (B) had diarrhea histories of longer durations (p \< 0.0001), and (C) had borderline lower WHZ score (p = 0.047), Hemoglobin concentrations were marginally lower in the Zambia cohort (p = 0.062) and there was no difference in tTG antibody circulating concentrations (as a percent of upper limit of normal, p = 0.16). Statistical analysis was performed by Mann-Whitney tests.

(TIF)

###### 

Click here for additional data file.

###### Scores of individual histology features between cohorts.

None of these cohorts had significant differences in (A) neutrophilic inflammation, (B) eosinophilic infiltration, and (C) foveolar metaplasia. Sample size: Pakistani n = 10, Zambian n = 16, GSE n = 13, control n = 6.

(TIF)

###### 

Click here for additional data file.

###### Individual histology heterogeneity in the Pakistani cohort.

The scores for each individual biopsy for each subject were plotted for (A) intraepithelial lymphocytes density, (B) goblet cell density, (C) Paneth cell density, and (D) chronic inflammation. These parameters showed some within-child variation, but less than the scores for villous architecture and intramucosal Brunner glands.

(TIF)

###### 

Click here for additional data file.
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Reviewer \#1: I am satisfied with the methods presented in this paper. In some instances the sample size in insufficient to ensure power, but this is clearly stated by the authors, and the analyses are correspondingly described as \'exploratory\' . Some additional analyses could be done (these are described under \'Major Comments\') but if I don\'t feel that these should be required.

Reviewer \#2: The terminology for the enteropathy in poorer countries has changed over the years and will no doubt continue to do so as the condition becomes better understood in specific populations as in this report. Referring to the condition being studied in this report as "EED" may be misleading. The term EED is generally used to describe the asymptomatic intestinal lesion that is universal in people exposed to poor sanitation and likely contributes to growth faltering in children. This is not the population studied here. Rather, these were selected groups of malnourished children who were either hospitalised with persistent diarrhoea or had not responded to standard nutritional therapy in the community. It is not known whether the intestinal lesion in these children represents the severe end of the spectrum of EED or perhaps one (or more) different gut pathologies. Indeed, figure 2 indicates clear differences in the intestinal lesion between the two malnutrition groups. It would be preferable if the terminology used for the gut lesion(s) studied in this report more closely related to the group studied rather than using "EED" as an umbrella term.

The objectives are clearly stated and the research design is appropriate given the difficulty of obtaining small intestinal biopsies in children. There is no formal sample size calculation but suffient children have been studied to assess the performance of the histology scoring system and identify major differences between the groups.

The status of the St. Louis controls is not clear. Are they children who had no GI pathology identified (i.e. "healthy" controls), or may they have had some GI pathology (e.g. reflux oesophagitis) although not GSE or a history of an inflammatory intestinal disorder? Please clarify the diagnoses, if any, in these controls -- and then use terminology for this group consistently throughout the paper. The term "non-GSE" implies that only GSE was excluded.

Methods of biopsy sample handling/processing and how biopsies were orientated across the sites to ensure reliable measurement of morphometric indices should be included (especially as villous architecture was the index that varied most between histopathologists).

Conclusions based on data presented. No ethical concerns.
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-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: The results are clear. Tables and Images are of sufficient quality, except for one supplemental figure (SF2) where the y-axis seems oddly scaled (possibly scaled to be equivalent to other figures, but the data are not really visible).

Reviewer \#2: The abstract should report on the performance of the histology scoring system and then on the findings according to patient group.

Given that WAZ does not distinguish between wasting and stunting and that the intestinal lesion may well differ between these two manifestations of malnutrition, analysis according to WAZ is difficult to interpret and could be removed.

Reviewer \#3: (No Response)
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**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: Conclusions are supported by the data described, limitations are honest, and the results of the work are useful.

Reviewer \#2: In the author summary, EED is referred to as a "disease". EED is found in children with intense and repeated intestinal exposure to enteropathogens -- yet, surprisingly, they remain mostly asymptomatic and without diarrhoea. It is conceivable, therefore, that EED is an appropriate adaptation to unsanitary environments that prevents frequent diarrhoea (and possibly diarrhoea mortality) albeit at the likely cost of growth faltering. Therefore, could the authors consider a term such as "condition" rather than "disease"?

Reviewer \#3: (No Response)
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**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: Major comments

The authors describe, "an index that will allow identification of histopathologic features unique to EED as well as those shared with other enteropathies´. It may be a question of terminology, but I question whether the tool that has been developed is 'an EED index', 'a histology severity index' or perhaps should instead be marketed as 'a checklist' of features to assess when examining a biopsy from a child with possible EED. This reflects the authors' own point, in the second-to-last paragraph, that insufficient information is yet available to determine which parameters should be included in an 'EED index', or how much weight those parameters should be given. And, while demonstrating that certain features can be reasonably reliably assessed is worthwhile, that doesn't really make it clear why it's better to add those features up. Relying too heavily on summary scores can also cause things to be overlooked. So, since the more pertinent histologic features of EED still are not known, continuing to analyze separate features separately seems more prudent, for the time being.

Relatedly, it would be helpful to better understand, overall & across features, whether the Zambian and Pakistani groups demonstrated a histologic phenotype differentiating them from the GSE group, and controls. PCA and cluster analysis might help to assess the relative similarity of the groups relative to each other. Those features that appeared to best differentiate both groups from the GSE group, and from controls, could be given the greater weight within the final index. The fact that the data presented suggests that the Zambian and Pakistani groups are rather dissimilar is both interesting and mildly concerning, since it indirectly raises the question of an EED phenotype actually exists.

As the authors themselves note, both 'EED' cohorts (Zambia & Pakistan) had wasting or severe wasting. The Zambian group had a further history of recent diarrhea. Therefore, it is really difficult to know to what extent observed changes to the small intestine was a result of 'severe acute malnutrition-induced enteropathy', versus the form of EED that might be present among children who are not wasted but stunted, or at risk of stunting. Why not re-title the paper, "... geographic-specific features of acute malnutrition-induced enteropathy..."?

It is also mildly concerning that lactulose:rhamnose and lactulose:mannitol ratios were not associated with histologic scores. On the other hand, given that each test was performed in a subset of the data, perhaps not too much weight should be given to this finding.

Minor comments

The statement. "EED is an underdiagnosed, highly prevalent condition among children in LMICs" in the introduction needs a citation.

In the sentence, "Based on existing data, we hypothesized that a histology index using an unbiased approach will allow identification of histopathologic features unique to EED as well as those shared with other enteropathies, and/or identify histologically-identifiable subsets of EED." It is not clear what existing data the authors are referring to.

A few sentences of the abstract and introduction are awkwardly written. For example, the following sentence could be broken in two: "The working hypothesis is that an environmental driver, including recurrent or persistent enteric infection, infections from specific pathogen(s), an abundance of nonpathogenic fecal microbes, or distortion of intestinal microbiota composition, precipitate and/or perpetuate the small bowel response, analogous to the small bowel response to gluten in gluten-sensitive enteropathy (GSE), also known as celiac disease."

It is unclear why the groups are described as 'cohorts', since, as described, only the Pakistani group appears to be part of a larger nested cohort, and the other 3 studies appear to have possibly been cross sectional.

Supplemental Figure 2 has a strange axis, nothing can really be seen. Since no outliers extend to the upper part of the y-axis, it is unclear why the range is so large.

Further speculation about what explains differences between Zambia and Pakistan would be welcomed.

Reviewer \#2: Page 8; include details of methodology and results for the lactulose:mannitol test.

Page 14: correct "Median tTG IgA concentrations as a percent of the upper limit of normal limit were ..."

Fig 1: clarify the meaning of the horizontal bars with \* in the legend.

Fig 2: clarify why only 8 and not 11 histology parameters are shown

Figs 1-3: it would be useful to clarify what the horizontal bars show (e.g. are these median and IQR?).

Tables 1 and 2: please keep the order of columns consistent between the tables (inc. Pakistan and Zambia).

Table 2 and 5: it is surprising that none of the GSE children had diarrhoea (and page 14); please comment. Table 2: It would be useful to add normal ranges for the lab tests in the left-hand column. Change "non-GSE control" to "Control" in footnote \* (as in comment above).

Table 3: The scoring range for Villous architecture 3 and 4 and for Enterocyte injury 1 and 2 do not include the value 50% for abnormality of mucosa

Supplementary Fig. 1 E; please clarify units on y axis

Reviewer \#3: (No Response)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: This is a useful paper that significantly advances the field of EED research. The work has been carefully done. I appreciate the effort to demonstrate inter-rater reliability as well as inter-biopsy reliability. Generally, the work leaves me scratching my head about the relationship of histological features to EED.

Reviewer \#2: This is a ground-breaking study of the development and initial findings of a scoring system for the intestinal pathology in children with malnutrition. The team of international collaborators that are leading research in this area are to be congratulated for overcoming the considerable challenges of undertaking endoscopy and biopsy safely in these highly vulnerable children. The histological scoring system will be of great value in further research in this area.

It would be useful to state that there were no adverse effects of endoscopy and biopsy (unless this has already been published elsewhere).

Reviewer \#3: The paper by Liu et al reports a new histological index of research and clinical value in the precise description of enteropathy. The study has the virtue of being jointly undertaken by clinicians and pathologists collaborating together. Its focus is not the general observation that  I have just made but focuses upon a very neglected area of the small intestinal enteropathy recognized to occur in children with suboptimal growth, now called environmental enteropathy within developing communities.

A comparison has been made of child patients from two communities in developing countries viz. Pakistan and Zambia with disease controls provided by child patients from St. Louis in USA with GSE , a developed community. It is not ethical to obtain small intestinal biopsies from "normal" in any of the three countries.

The more general value of this paper is that it produces evidence for the value of a comprehensive reproducible histological framework to categorize small intestinal enteropathy.

The histological data and the way it was produced from the three communities is clearly documented with aN indication of reproducibility (inter observer reproducibility), with rigorous testing. Care has been taken to harmonise the assessment from the three communities. The EED Biopsy Initiative Consortium is a fine example of international  collaborative study.

The area studied is of considerable clinical importance from the perspective of paediatric gastroenterology and beyond in the realm of nutrition.

Comparison between environmental enteropathy and GSE is important in communities such as Pakistan, where both may occur. It is important to observe that IEL histology scores for IEL were elevated for GSE in St. Louis (2.7) and in Pakistan (2.6) compared to Zambia (0.7). Elevated IEL's are a well known histological feature of GSE but this has also been described in experimental animals (MacDonald and Ferguson 1978) and in humans (Wright et al 1977). Giardia can be recognized histologically on the surface of the mucosa of children with giardiasis, presumably this was not observed but it would be a helpful addition to the paper to have a comment that there was no histological evidence of giardia lamblia.

MACDONALD TT and FERGUSON A (1978) Small intestinal epithelial kinetics and protozoal infection in mice

Gastroenterology 74 496-500

WRIGHT SG, TOMKINS AM and RIDLEY (1977) Giardiasis: clinical and therapeutic aspects Gut 18 343 -- 350k

The overall result is really just a beginning as there clearly needs to be further studies of this neglected area. These may indeed pave the way for future therapeutic endeavours.

Overall I strongly recommend publication of this paper which may indeed in the future be regarded as a seminal paper for the systematic evaluation of histology in children with small intestinal enteropathy.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--
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Dear Dr. Liu,

We are pleased to inform you that your manuscript, \"A novel histological index for evaluation of environmental enteric dysfunction identifies geographic-specific features of enteropathy among children with suboptimal growth\", has been editorially accepted for publication at PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please note: your manuscript will not be scheduled for publication until you have made the required changes.

IMPORTANT NOTES

\* Copyediting and Author Proofs: To ensure prompt publication, your manuscript will NOT be subject to detailed copyediting and you will NOT receive a typeset proof for review. The corresponding author will have one final opportunity to correct any errors when sent the requests mentioned above. Please review this version of your manuscript for any errors.

\* If you or your institution will be preparing press materials for this manuscript, please inform our press team in advance at <plosntds@plos.org>. If you need to know your paper\'s publication date for media purposes, you must coordinate with our press team, and your manuscript will remain under a strict press embargo until the publication date and time. PLOS NTDs may choose to issue a press release for your article. If there is anything that the journal should know, please get in touch.

\*Now that your manuscript has been provisionally accepted, please log into EM and update your profile. Go to <http://www.editorialmanager.com/pntd>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

\*Note to LaTeX users only - Our staff will ask you to upload a TEX file in addition to the PDF before the paper can be sent to typesetting, so please carefully review our Latex Guidelines \[<http://www.plosntds.org/static/latexGuidelines.action>\] in the meantime.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Margaret Kosek

Associate Editor

PLOS Neglected Tropical Diseases

Andrew Azman

Deputy Editor
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20 Dec 2019

Dear Dr. Liu,

We are delighted to inform you that your manuscript, \"A novel histological index for evaluation of environmental enteric dysfunction identifies geographic-specific features of enteropathy among children with suboptimal growth,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Serap Aksoy

Editor-in-Chief

PLOS Neglected Tropical Diseases

Shaden Kamhawi

Editor-in-Chief

PLOS Neglected Tropical Diseases
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